Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.

Gunnarsson N, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richter J, Wadenvik H, Wallvik J, Själander A.

Br J Haematol. 2015 Jun;169(5):683-8. doi: 10.1111/bjh.13346. Epub 2015 Mar 27.

PMID:
25817799
2.

Altered cytokine levels in pediatric ITP.

Jernås M, Hou Y, Strömberg Célind F, Shao L, Wang Q, Ju X, Mellgren K, Wadenvik H, Hou M, Olsson B.

Platelets. 2015 Mar 25:1-4. [Epub ahead of print]

PMID:
25806433
3.

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).

Jernås M, Malmeström C, Axelsson M, Nookaew I, Wadenvik H, Lycke J, Olsson B.

BMC Immunol. 2013 Jul 29;14:32. doi: 10.1186/1471-2172-14-32.

4.

Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP.

Jernås M, Hou Y, Strömberg Célind F, Shao L, Nookaew I, Wang Q, Ju X, Mellgren K, Wadenvik H, Hou M, Olsson B.

Blood. 2013 Sep 5;122(10):1789-92. doi: 10.1182/blood-2013-05-502807. Epub 2013 Jul 18.

5.

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevärn B, Myhr-Eriksson K, Ohm L, Olsson-Strömberg U, Själander A, Wadenvik H, Simonsson B, Stenke L, Richter J.

Blood. 2013 Aug 15;122(7):1284-92. doi: 10.1182/blood-2013-04-495598. Epub 2013 Jul 10.

6.

MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP).

Jernås M, Nookaew I, Wadenvik H, Olsson B.

Blood. 2013 Mar 14;121(11):2095-8. doi: 10.1182/blood-2012-12-471250. Epub 2013 Jan 9.

7.

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group.

Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.

8.

Differential expression of T-cell genes in blood and bone marrow between ITP patients and controls.

Jernås M, Nookaew I, Wadenvik H, Olsson B.

Thromb Haemost. 2013 Jan;109(1):112-7. doi: 10.1160/TH12-07-0468. Epub 2012 Nov 8.

PMID:
23138397
9.

Serum levels of LIGHT in MS.

Malmeström C, Gillett A, Jernås M, Khademi M, Axelsson M, Kockum I, Mattsson N, Zetterberg H, Blennow K, Alfredsson L, Wadenvik H, Lycke J, Olsson T, Olsson B.

Mult Scler. 2013 Jun;19(7):871-6. doi: 10.1177/1352458512463766. Epub 2012 Oct 4.

PMID:
23037546
10.

MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.

Jernås M, Malmeström C, Axelsson M, Olsson C, Nookaew I, Wadenvik H, Zetterberg H, Blennow K, Lycke J, Rudemo M, Olsson B.

Mult Scler. 2013 Apr;19(4):403-10. doi: 10.1177/1352458512455466. Epub 2012 Aug 20.

PMID:
22907940
11.

Increased plasma levels of granzymes in adult patients with chronic immune thrombocytopenia.

Olsson B, Jernås M, Wadenvik H.

Thromb Haemost. 2012 Jun;107(6):1182-4. doi: 10.1160/TH12-01-0012. Epub 2012 Apr 4. No abstract available.

PMID:
22476618
12.

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.

Jönsson S, Standal T, Olsson B, Mellström D, Wadenvik H.

Am J Hematol. 2012 May;87(5):550-2. doi: 10.1002/ajh.23155. Epub 2012 Mar 9.

PMID:
22407760
13.

Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.

Jönsson S, Olsson B, Söderberg J, Wadenvik H.

Ann Hematol. 2012 May;91(5):679-85. doi: 10.1007/s00277-011-1359-0. Epub 2011 Nov 3.

PMID:
22048790
14.

Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

J Bone Miner Metab. 2012 Jan;30(1):119-23. doi: 10.1007/s00774-011-0323-3. Epub 2011 Oct 14.

PMID:
21993629
15.

Increased number of B-cells in the red pulp of the spleen in ITP.

Olsson B, Ridell B, Jernås M, Wadenvik H.

Ann Hematol. 2012 Feb;91(2):271-7. doi: 10.1007/s00277-011-1292-2. Epub 2011 Jul 23.

PMID:
21785982
16.

BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.

Jönsson S, Olsson B, Jacobsson S, Palmqvist L, Ricksten A, Ekeland-Sjöberg K, Wadenvik H.

Scand J Clin Lab Invest. 2011 Feb;71(1):7-11. doi: 10.3109/00365513.2010.521981. Epub 2010 Sep 23.

PMID:
20863169
17.

The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia.

Grund S, Olsson B, Jernås M, Jacobsson S, Swolin B, Nabi IR, Carlsson L, Wadenvik H.

Med Oncol. 2011 Dec;28(4):1542-8. doi: 10.1007/s12032-010-9555-7. Epub 2010 Jun 24.

PMID:
20574759
18.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators.

N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.

19.

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T.

Leukemia. 2010 Jul;24(7):1357-9. doi: 10.1038/leu.2010.84. Epub 2010 May 20. No abstract available.

PMID:
20485368
20.

[New therapeutic possibilities in chronic ITP in adults].

Jönsson S, Olsson B, Wadenvik H.

Lakartidningen. 2009 May 20-Jun 2;106(21-22):1476-9. Review. Swedish. No abstract available.

PMID:
19579436
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk